论文信息 - A Phase II Trial of Trifluridine/Tipiracil in Combination with Cetuximab Rechallenge in Patients with RAS Wild-Type mCRC Refractory to Prior Anti-EGFR Antibodies: WJOG8916G Trial - 字舞流文

A Phase II Trial of Trifluridine/Tipiracil in Combination with Cetuximab Rechallenge in Patients with RAS Wild-Type mCRC Refractory to Prior Anti-EGFR Antibodies: WJOG8916G Trial

K. Nishio | K. Muro | Yoshiyuki Yamamoto | N. Boku | T. Moriwaki | M. Shimokawa | H. Shoji | T. Kajiwara | H. Kawakami | H. Hara | T. Esaki | N. Takahashi | Y. Sunakawa | Toshihiko Matsumoto | K. Sugiyama | N. Takegawa | T. Masuishi | Y. Narita | N. Izawa | N. Aomatsu | C. Kondoh | T. Eguchi Nakajima | K. Kawakami